Schattauer 出版社
期刊
会议
图书
作者:Kathelijn Fischer , Margaret Ragni ...
来源:[J].Thromb Haemost(IF 6.094), 2017, Vol.117 (3), pp.508-518Schattauer 出版社
摘要:The safety, efficacy, and prolonged half-life of recombinant factor IX Fc fusion protein (rFIXFc) were demonstrated in the Phase 3 B-LONG (adults/adolescents ≥12 years) and Kids B-LONG (children <12 years) studies of subjects with haemophilia B (≤2 IU/dl). Here, we rep...
作者:Kathelijn Fischer , Victor Blanchette ...
来源:[J].Thromb Haemost(IF 6.094), 2017, Vol.117 (6), pp.1023-1030Schattauer 出版社
摘要:The prophylactic administration of factor IX (FIX) is considered the most effective treatment for haemophilia B. The inter-individual variability and complexity of the pharmacokinetics (PK) of FIX, and the rarity of the disease have hampered identification of an optimal treatment...
作者:... Roger E. G. Schutgens , Yvonne T. van der Schouw , Kathelijn Fischer
来源:[J].Thromb Haemost(IF 6.094), 2016, Vol.115 (5), pp.931-938Schattauer 出版社
摘要:Prophylaxis is the recommended treatment for children with severe haemophilia A, but whether prophylaxis should be continued in adulthood is still under debate. Previous studies with limited follow-up have suggested that some patients may be able to stop prophylaxis in adult...
作者:Kathelijn Fischer , Pia Petrini ...
来源:[J].Thromb Haemost(IF 6.094), 2016, Vol.115 (4), pp.729-737Schattauer 出版社
摘要:Many studies have reported an increased incidence of inhibitors in previously untreated patients (PUPs) with severe haemophilia A after the introduction of recombinant products. It was the objective of this study to investigate whether the inhibitor incidence has increased b...
作者:Kathelijn Fischer , Manuel Carcao ...
来源:[J].Thromb Haemost(IF 6.094), 2016, Vol.115 (5), pp.913-920Schattauer 出版社
摘要:Current therapy for haemophilia A is guided by severity of the disease, which in turn is best reflected in patients’ endogenous factor VIII activity levels. For patients with severe haemophilia (particularly children), prophylaxis with continuous routine factor replacement ...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×